Live feed07:45:00·946dPRReleasevia QuantisnowCybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single DoseByQuantisnow·Wall Street's wire, on your screen.CYBN· Cybin Inc.Health Care
